MX2019005450A - Composiciones y metodos farmaceuticos. - Google Patents
Composiciones y metodos farmaceuticos.Info
- Publication number
- MX2019005450A MX2019005450A MX2019005450A MX2019005450A MX2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A MX 2019005450 A MX2019005450 A MX 2019005450A
- Authority
- MX
- Mexico
- Prior art keywords
- promoter
- methods
- subject
- pharmaceutical compositions
- inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 8
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 abstract 3
- 102000002704 Leucyl aminopeptidase Human genes 0.000 abstract 3
- 108010004098 Leucyl aminopeptidase Proteins 0.000 abstract 3
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
Abstract
Se proporcionan composiciones farmacéuticas y equipos que incluyen un inhibidor de tirosina hidroxilasa; melanina, un promotor de melanina, o una combinación de los mismos; un promotor p450 3A4; y un inhibidor de leucina aminopeptidasa. También se proporcionan métodos para tratar el cáncer en un sujeto, que comprenden administrar una cantidad efectiva de un inhibidor de tirosina hidroxilasa, un promotor de melanina, un promotor p450 3A4 y un inhibidor de leucina aminopeptidasa al sujeto con necesidad del mismo. También se proporcionan métodos para reducir la proliferación celular en un sujeto que comprende administrar una cantidad efectiva de un inhibidor de tirosina hidroxilasa, un promotor de melanina, un promotor p450 3A4 y un inhibidor de leucina aminopeptidasa al sujeto con necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/351,966 US10272068B2 (en) | 2012-01-17 | 2016-11-15 | Pharmaceutical compositions and methods |
| PCT/US2017/061682 WO2018093820A1 (en) | 2016-11-15 | 2017-11-15 | Pharmaceutical compositions and methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005450A true MX2019005450A (es) | 2019-07-04 |
Family
ID=60570232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005450A MX2019005450A (es) | 2016-11-15 | 2017-11-15 | Composiciones y metodos farmaceuticos. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3541411A1 (es) |
| JP (2) | JP2019537608A (es) |
| KR (2) | KR20230003314A (es) |
| CN (1) | CN110167580A (es) |
| AU (1) | AU2017361080A1 (es) |
| BR (1) | BR112019009799A2 (es) |
| CA (1) | CA3040922A1 (es) |
| EA (1) | EA201991192A1 (es) |
| IL (1) | IL266486A (es) |
| MX (1) | MX2019005450A (es) |
| PH (1) | PH12019500758A1 (es) |
| WO (1) | WO2018093820A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3968785A4 (en) | 2019-05-14 | 2023-01-11 | Tyme, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| WO2021076723A1 (en) * | 2019-10-15 | 2021-04-22 | Tyme, Inc. | Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer |
| IL294803A (en) * | 2020-01-17 | 2022-09-01 | Tyme Inc | Tyrosine derivatives for modulating cancer |
| CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
| JP2023553011A (ja) * | 2020-12-02 | 2023-12-20 | ホフマン・テクノロジーズ・エルエルシー | 非ヒト哺乳動物においてがんを調節するための組成物および方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225435A (en) | 1990-05-18 | 1993-07-06 | Yale University | Soluble melanin |
| WO2006036892A2 (en) * | 2004-09-24 | 2006-04-06 | Sapphire Therapeutics, Inc. | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| WO2006032299A1 (en) * | 2004-09-24 | 2006-03-30 | Susanna Miettinen | Use of inhibitors of 24-hydroxylase in the treatment of cancer |
| US8481498B1 (en) * | 2012-01-17 | 2013-07-09 | Steven Hoffman | Pharmaceutical compositions and methods |
| US20130183263A1 (en) * | 2012-01-17 | 2013-07-18 | Steven Hoffman | Pharmaceutical compositions and methods |
| NZ628757A (en) * | 2012-01-17 | 2016-07-29 | Tyme Inc | Pharmaceutical compositions and methods for treating cancer |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-11-15 WO PCT/US2017/061682 patent/WO2018093820A1/en not_active Ceased
- 2017-11-15 AU AU2017361080A patent/AU2017361080A1/en not_active Abandoned
- 2017-11-15 CN CN201780070447.8A patent/CN110167580A/zh active Pending
- 2017-11-15 EP EP17808688.0A patent/EP3541411A1/en not_active Withdrawn
- 2017-11-15 KR KR1020227043322A patent/KR20230003314A/ko not_active Ceased
- 2017-11-15 CA CA3040922A patent/CA3040922A1/en active Pending
- 2017-11-15 MX MX2019005450A patent/MX2019005450A/es unknown
- 2017-11-15 EA EA201991192A patent/EA201991192A1/ru unknown
- 2017-11-15 JP JP2019524973A patent/JP2019537608A/ja active Pending
- 2017-11-15 BR BR112019009799A patent/BR112019009799A2/pt not_active Application Discontinuation
- 2017-11-15 KR KR1020197016782A patent/KR20190084291A/ko not_active Ceased
-
2019
- 2019-04-08 PH PH12019500758A patent/PH12019500758A1/en unknown
- 2019-05-06 IL IL266486A patent/IL266486A/en unknown
-
2022
- 2022-11-18 JP JP2022184577A patent/JP2023018029A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023018029A (ja) | 2023-02-07 |
| IL266486A (en) | 2019-07-31 |
| JP2019537608A (ja) | 2019-12-26 |
| KR20190084291A (ko) | 2019-07-16 |
| EP3541411A1 (en) | 2019-09-25 |
| BR112019009799A2 (pt) | 2019-08-06 |
| CA3040922A1 (en) | 2018-05-24 |
| AU2017361080A1 (en) | 2019-05-02 |
| EA201991192A1 (ru) | 2019-10-31 |
| WO2018093820A1 (en) | 2018-05-24 |
| PH12019500758A1 (en) | 2019-07-24 |
| CN110167580A (zh) | 2019-08-23 |
| KR20230003314A (ko) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501639B1 (en) | Pharmaceutical compositions and methods | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| EA201890961A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
| MX2017001656A (es) | Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas. | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MX2018002344A (es) | Metodo para tratar el cancer. | |
| MX2018007266A (es) | Combinaciones para el tratamiento del cancer. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2018012511A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| HK1258319A1 (zh) | 癌症疗法 | |
| MX2022002699A (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| EP4640237A3 (en) | Macrophage-based therapy for use in the treatment of acute liver injury |